Skip to main content
Preclinical data, simple endpoints, adaptive design boost trial success odds

Controlled human infection modeling and adaptive clinical trial design have the potential to reduce the odds that late-stage clinical trials will fail, says SGS Life Sciences Scientific Director Adrian Wildfire. Adaptive design enables researchers to follow clues and adjust to early findings, but adaptive design might not be needed in trials with simple endpoints, says Wildfire, who adds that researchers should thoroughly analyze preclinical data before designing later trial stages.

Full Story: